您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

蔡明釗醫師

病毒性肝炎診治、肝硬化肝衰竭診治、肝癌藥物治療、肝腫瘤消融治療、診斷性超音波、介入性超音波診治、腸道微菌叢移植
  • 國語,英語,閩南語
  • 助理教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚紀念醫院 胃腸肝膽科系 教授級主治醫師(2024.07)
    • 高雄長庚紀念醫院 胃腸肝膽科系 肝臟科負責人(2023.07)
    • 中山大學 後醫學系專任助理教授
  • 學歷
    • 中國醫藥大學中醫學系畢
    • 長庚大學臨床醫學研究所博士班畢業(2022.01)
    • 美國西奈山醫院Mount Sinai Hospital 進修
    • ---肝臟移植後纖維化分子生物醫學暨臨床移植肝臟醫學研究(2014.7~2016.6)
  • 經歷
    • 高雄長庚紀念醫院 胃腸肝膽科系病房主任
    • 高雄長庚醫院內科部住院醫師
    • 高雄長庚醫院胃腸肝膽科系研究員
    • 高雄縣鳳山醫院胃腸肝膽科主治醫師
    • 長庚大學 醫學系兼任助理教授
  • 學會與認證
    • 台灣內科醫學會內科專科醫師及指導醫師
    • 台灣消化系醫學會消化系內科專科醫師
    • 台灣消化系內視鏡醫學會消化系內視鏡專科醫師
    • 台灣肝癌醫學會專科醫師
    • 台灣腫瘤消融學會認證肝腫瘤消融手術醫師
  • 論文及期刊發表
    • Huynh CN#, Tsai YC#, Tsai MJ, Tsai CJ, Wang CC, Lin CC, Yen YH, Hung CH, Kuo YH, Tai WC, Hu TH, Tsai MC*. Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B. Am J Cancer Res. 2024 Sep 25;14(9):4567-4579. (SCI)
      慢性B型肝炎中早期肝細胞癌根治性切除後同時存在MASLD的影響
    • Lin YP, Tsai YC, Tsai MJ, Huang PY, Chen CH, Yao CC, Chuah SK, Kuo YH, Tai WC, Lian WS, Fang HW, Hu TH, Tsai MC*. Effect of gut microbiota and PNPLA3 polymorphisms on nonalcoholic fatty liver disease in lean and obese individuals. Adv Dig Med. 2024 Sep;11:129–139.
      腸道微生物和 PNPLA3 基因多型性對瘦和肥胖非酒精性脂肪肝的影響
    • Cho WR, Wang CC, Tsai MJ, Lin CC, Yen YH, Chen CH, Kuo YH, Yao CC, Hung CH, Huang PY, Liu AC, Tsai MC*. Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma. Clin Med Insights Oncol. 2024 Mar 5:18:11795549241228232. (SCI)
      抽菸是早期肝癌手術切除後晚期復發的危險因子
    • Tsai MC, Yong CC, Lin CC, Lee WC, Wang CC, Hung CH, Chen IH, Cheng YF, Hsiao CC*, Hu TH*, Chen CL. Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma. HepatoBiliary Surg Nutr. 2023 Apr;12(2):169-182. (SCI)
      活體肝臟移植治療BCLC中期肝細胞癌
    • Huang PY, Chen CH, Tsai MJ, Yao CC, Wang HM, Kuo YH, Chang KC, Hung CH, Chuah SK, Tsai MC*. Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C. J Formos Med Assoc. 2023 Feb;122(2):157-163. (SCI)
      Ｃ型肝炎病毒清除對腸道菌落的影響
    • Wang YC, Tsai MC(co-first), Chen YS(co-first), Hsieh PM, Hung CM, Lin HY, Hsu YC, Yeh JH, Hsiao PJ, Su YC, Ma CH, Lee CY, Lin CC, Shu CW , Li YC, Tsai MH, Yu Lin JY , Peng WH, Yu ML, Lin CW*. NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. Hepatol Commun. 2022 Dec;6(12):3563-3577.
      NPRL2的下調可透過MTOR路徑和抑制AUTOPHAGY來促進肝細胞癌的生長
    • Tsai MC, Yang SS, Lin CC, Wang WL, Hsu YC, Chen YS, Hu JT, Lin JY, Yu ML, Lin CW*. Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis. JAMA Netw Open. 2022 Jul 1;5(7):e2223511. (SCI)
      B型肝炎病毒相關肝硬化患者重度酒精攝入和ALDH2 rs671基因多型性與肝細胞癌和死亡率的關係
    • Huang DS, Liu TT, Lu WT, Wang CC, Lin CC, Yong CC, Chen KD, Liu YW, Kuo YH, Yen YH, Hu TH, Tsai MC*. Comparison of portal and capsular microscopic vascular invasion in the outcomes of early HCC after curative resection. Am J Cancer Res. 2022 Jun 15;12(6):2659-2672. (SCI)
      比較微小門脈血管與包膜血管侵犯對早期肝癌術後預後的影響
    • Chuang CH, Chen PC, Bai CH, Wu YL, Tsai MC*, Li CY. Association between Spinal Cord Injury and Alcohol Dependence: A Population-Based Retrospective Cohort Study. J Pers Med. 2022 Mar 16;12(3):473. (SCI)
      脊髓損傷與酒精依賴的關係-根據大規模縱貫性健保資料庫分析
    • Chen YS, Huang KH, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Lin YP, Tsai MC*. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma. Medicina (Kaunas). 2022 Feb 9;58(2):259. (SCI)
      C型肝炎直接抗病毒治療對早期肝癌根除性切除後復發風險的影響
    • Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Tsai MC*. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. Front Oncol. 2022 Feb 2;12:816472. (SCI)
      Non-B non-C早期肝癌的代謝性風險因子增加:一項為期10年的追蹤研究
    • Tsai MC, Wang CC, Lee WC, Lin CC, Chang KC, Chen CH, Hung CH, Lin MT, Hsiao CC, Chen CL, Chien RN, Hu TH*. Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. Liver Cancer. 2022 Jan;11:22–37. (SCI)
      TDF對BCLC第0和A期肝癌根除性切除術後的三級預防優於ETV
    • Tsai MC, Hung CH, Lu SN, Wang JH, Chen CH, Kee KM, Chang KC, Chao TL, Hu TH*. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan. Biomed J. 2021 Dec;44(6S1):S126-S131. (SCI)
      台灣C型肝炎基因型1a和1b亞型中在NS5A耐藥性相關變異的發生率
    • Chen YS#, Yang SY#, Wang PM, Wang CC, Yong CC, Chen DW, Liu YW, Chuang CH, Huang PY, Yao CC, Lin YP, Tsai MC*. Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. J Pers Med. 2021 Nov 30;11(12):1261.
      同時切除膽囊與降低早期肝癌病人手術後復發率相關:一個單一中心十年的觀察性研究
    • Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC*. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol. 2021 Oct 19;21(1):386. (SCI)
      術前ALBI分級可預測非B非C肝癌患者接受根除性切除的預後
    • Lin YP#, Lin SH#, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC*. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med. 2021 Jul 21;11(8):684. (SCI)
      代謝相關性脂肪肝對B型肝炎相關之0/A 期肝細胞癌患者接受根治性切除後的的影響
    • Tsai MC, Lin CC, Chen DW, Liu YW, Wu YJ, Yen YH, Huang PY, Yao CC, Chuang CH, Hsiao CC*. The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. Medicina (Kaunas). 2021 Jun 4;57(6):574. (SCI)
      蛋白激活受體2在肝細胞癌接受切除後的角色
    • Cho WR, Wang CC, Tsai MY, Chou CK, Liu YW, Wu YJ, Lin MT, Chen KD, Chuang CH, Huang PY, Hu TH, Tsai MC*. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS One. 2021 Mar 4;16(3):e0247231. (SCI)
      METFORMIN對糖尿病患者初次肝切除後肝細胞癌復發的影響
    • Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC*. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer. 2021 Jan 15;21(1):70. (SCI)
      Statin與降低BCLC期別0-A肝癌病人手術後復發率相關
    • Tsai MC, Chang KC, Yen YH, Wu CK, Lin MT, Hu TH*.Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites. Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):208-213. (SCI)
      tenofovir和entecavir在慢性Ｂ型肝炎肝硬化頑固性腹水患者造成急性腎損傷的比較
    • Cho WR, Hung CH, Chen CH, Lin CC, Wang CC, Liu YW, Wu YJ, Yong CC, Chen KD, Tsai YC, Hu TH, Tsai MC*. Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. Sci Rep. 2020 Apr 29;10(1):7290. (SCI)
      術後ALBL grade 預測治癒性肝癌切除預後的能力
    • Tsai MC*, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients. 2020 Mar 19;12(3):820. (SCI)
      經切片診斷非酒精性脂肪肝病人的腸道微菌態失衡:一個台灣橫斷性研究
    • Tsai MC, Huang CC, Wei YC, Liu TT, Lin MT, Yi LN, Lin PR, Wang CC, Chu TH, Hsiao CC, Hu TH*, Tai MH*. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2020 Mar 17;21(6):2060. (SCI)
      合併CHIBBY和BETA-CATENIN可預測肝癌病人的預後
    • Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC*. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020 Jan;44(1):247-257. (SCI)
      ALBI分級是良好的預測模型用以預測肝癌切除後的晚期復發
    • Tsai MC, Yen YH, Chang KC, Hung CH, Chen CH, Lin MT, Hu TH*. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 2019 Dec 2;19(1):1169. (SCI)
      血清裡升高的UPA可用來預測肝癌切除後不良的預後
    • Tsai MY, Yen YH, Huang PY, Sou FM, Lin CC, Cho WR, Wang HM, Chen DW, Chang KC, Wu CK, Hu TH, Tsai MC*. The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection. Gastroenterol Res Pract. 2019 Dec 1;2019:8945798. (SCI)
      術前及術後的FIB-4可作為慢性B型肝炎併肝癌接受腫瘤切除術後的預後指數
    • Tsai MC#, Lin CY#, Hung CH, Lu SN, Tung SY, Chien RN, Lin CL, Wang JH, Chen CH, Chang KC, Hu TH*, Sheen IS*. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. J Viral Hepat. 2019 Dec;26(12):1404-1412. (SCI)
      直接抗病毒藥物治療C型肝炎病患對腎功能的影響：真實世界的經驗
    • Huang PY, Wang CC, Lin CC, Lu SN, Wang JH, Hung CH, Kee KM, Chen CH, Chen KD, Hu TH, Tsai MC*. Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. J Clin Med. 2019 Oct 14;8(10):1676. (SCI)
      發炎分數在早期肝癌經手術治療的預後相關性探討
    • Tsai MC, Chen CH, Hu TH, Lu SN, Lee CM, Wang JH, Hung CH*.Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med Assoc. 2017 July; 116(7)512-521. (SCI)
      口服抗病毒藥物治療慢性B行肝炎肝硬化的長期預後
    • Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Chang KC, Yen YH, Lin MT, Hu TH*. Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study. PLoS One. 2016 Mar 10;11(3):e0149761. (SCI)
      核?酸類似物是否影響慢性B型肝炎併腎功能不全病人的腎臟功能？一縱貫性研究
    • Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH*. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016 Jan;22(1):95.e1-7. (SCI)

    • Tsai MC, Yu HC(co-first), Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH*, Hu TH*. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014 Mar;29(3):568-75. (SCI)

    • Tsai MC, Chen CH*, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH*. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014 Feb;20(2):090-0100. (SCI)

    • Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH*. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother. 2012 Mar;67(3):696-9. (SCI)

    • Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH*. Hepatitis B virus infection and renal transplantation. World J Gastroenterol. 2010 Aug 21;16(31):3878-87. Review. (SCI)

    • Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, Hu TH, Chen CH, Lu SN*. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010 Mar;25(3):605-12. (SCI)

    • Tsai MC, Lin MC, Hung CH*. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis. J Formos Med Assoc. 2009 Sep;108(9):746-50. (SCI)

    • Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH*. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol. 2009 Feb;50(2):281-8. (SCI)

    • Tsai MC, Lin JW, Lin SE, Chen HH, Lee CM, Hu TH*. Prognostic analysis of rectal stromal tumors by reference of National Institutes of Health risk categories and immunohistochemical studies. Dis Colon Rectum. 2008 Oct;51(10):1535-43. (SCI)